Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.

Plain-language guide to PMID 38368603 (2024): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 38368603
Journal: Clinical endocrinology
Year: 2024
Study type: Randomized Controlled Trial
Authors: Mori J et al. (8 authors)
DOI: 10.1111/cen.15025
Registered trial: NCT03811535

What This Study Did, in Plain Language

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Somapacitan is a long-acting growth hormone (GH) derivative developed for the treatment of GH deficiency (GHD).

Who Took Part

The age groups tagged for this paper are children.

Subanalysis on Japanese patients from a randomised, open-labelled, controlled parallel-group phase 3 trial (REAL4, NCT03811535).

Height velocity (HV; cm/year) at Weeks 52 and 104 were the primary measurements.

How the Study Was Run

The design is described as randomized, open-label and parallel-group.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.

The Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group ran side by side rather than switching.

Additional assessments included HV SD score (SDS), height SDS, bone age, insulin-like growth factor-I (IGF-I) SDS, and observer-reported outcomes.

What Was Measured

Topics PubMed links to this paper include Growth Hormone, Insulin-Like Growth Factor I, Japan, Human Growth Hormone, Dwarfism, Pituitary, Histidine and Mannitol.

The authors tagged it with the keywords clinical trial, growth hormone deficiency, growth hormone replacement therapy, long-acting growth hormone and somapacitan.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.